Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Хронический вирусный гепатит С

Список литературы

  1. EASL recommendations on treatment of hepatitis C: Final update of the series. J Hepatol 2020 Nov;73(5):1170-1218. 
  2. Dubuisson J, Cosset FL. Virology and cell biology of the hepatitis C virus life cycle: an update. J Hepatol. 2014;61(1 Suppl):3-13.
  3. Sergio M Borgia, et al. Identification of a novel hepatitis c virus genotype from punjab, india: expanding classification of hepatitis c virus into 8 genotypes. J Infect Dis. 2018 Oct 20;218(11):1722-1729.
  4. Дунаева, Н. В. Структурно-функциональная организация генома вируса гепатита С. Вопросы вирусологии. – 2006. – № 51 (2). – С. 10 – 14.
  5. Irshad M, Gupta P, Irshad K. Immunopathogenesis of liver injury during hepatitis c virus infection. Viral Immunol. 2019;32(3):112-205.
  6. Lingala S, Ghany MG. Natural history of hepatitis C. Gastroenterol Clin North Am. 2015;44(4):717-34.
  7. Yamane, D. Liver injury and disease рathogenesis in chronic hepatitis C. Curr Top Microbiology Immunology 2013;369:263-288.
  8. Семенов, А. В. Особенности популяционного состава CXCRS-положительных лимфоцитов периферической крови больных хроническим гепатитом С. Журнал микробиологии, эпидемиологии и иммунобиологии. – 2013. –№ 6. – С. 69 – 76.
  9. Елезов, Д. С. Анализ популяций Т-хелперных клеток памяти, экспрессирующих хемокиновые рецепторы CXCR3 и CCR6, в периферической крови больных хроническим вирусным гепатитом С. Бюллетень экспериментальной биологии и медицины. – 2015. – № 160 (8). – С. 204 – 208.
  10. Lohr, H. F. HCV replication in mononuclear cells simulates anti-HCV-secreting B cells and reflects nonresponsiveness to interferon-alfa. J. Med. Virol. 1995;46(4):314-21.
  11. Арсентьева, Н. А. Хемокиновые рецепторы CXCR3 и CCR6 и их лиганды в печени и крови больных хроническим вирусным гепатитом С. Бюллетень экспериментальной биологии и медицины. – 2015. – № 8. – С. 218 – 222.
  12. Давидович, Н. В. Иммунный ответ при вирусном гепатите С: ведущая роль натуральных киллеров. Ж. «Вестник Северного (Арктического) федерального университета». – 2015. – №4. – C. 68 – 78.
  13. Хронический вирусный гепатит. Под ред. В. В. Серова, З. Г. Апросиной. – М: Медицина. – 2002. – 384 с.
  14. Дудина, К. Р. Факторы прогрессирующего течения хронического гепатита С. Ж. Лечащий врач. – 2013. – №10. – С. 36.
  15. Сухорук, А. А. Цирроз печени как исход хронического гепатита С. Журнал инфектологии. – 2014. –№ 6(1). – С. 67 – 71.
  16. Пименов Н.Н., Комарова С.В., Карандашова И.В., Цапкова Н.Н., Волчкова Е.В., Чуланов В.П. Гепатит С и его исходы в России: анализ заболеваемости, распространенности и смертности до начала программы элиминации инфекции. Инфекционные болезни, 2018, т.16, №3, с. 37-45
  17.  WHO Global hepatitis report, 2018 https://www.who.int/news-room/fact-sheets/detail/hepatitis-c Обращение к сайту в мае 2021.
  18. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13(17):2436-41.
  19. Terrault NA. Sexual activity as a risk factor for hepatitis C. Hepatology. 2002;36(5 Suppl 1):99-105.
  20. Chan DP, Sun HY, Wong HT, Lee SS, Hung CC. Sexually acquired hepatitis C virus infection: a review. Int J Infect Dis. 2016;49:47-58.
  21. Жданов, К. В. Вирусные гепатиты. СПб.: Фолиант. – 2011. – 304 с.
  22. Wang LS, D"souza LS, Jacobson IM. Hepatitis C – a clinical review. J Med Virol. 2016;88(11):1844-55.
  23. Kuna L, Jakab J, Smolic R, Wu GY, Smolic M. HCV Extrahepatic Manifestations. J Clin Transl Hepatol. 2019;7(2):172-182.
  24. Ющук, Н. Д. Инфекционные болезни: национальное руководство – 2-е изд., переработанное и доп. М.: ГЭОТАР-Медиа, 2019. – 1104 с.
  25. Майер, К. П. Гепатит и последствия гепатита. Практич. рук. Пер. с нем. – 2-е изд.// М: ГЭОТАР- МЕД, 2004. – С. 265, 467 – 479; 491 – 503.
  26. Сухорук, А. А. Цирроз печени как исход хронического гепатита С. Журнал инфектологии. – 2014. – Т. 6, № 1. – С. 67 – 71.
  27. Билалова, А. Р. Клинико-лабораторная характеристика хронических гепатитов и циррозов печени различной этиологии. Архивъ внутренней медицины. – 2015. – № 2(22). – С. 8 – 14.
  28. Chevaliez S, Soulier A, Poiteau L, Bouvier-Alias M, Pawlotsky JM. Clinical utility of hepatitis C virus core antigen quantification in patients with chronic hepatitis C. J Clin Virol 2014;61:145–148.
  29. Heidrich B, Pischke S, Helfritz FA, Mederacke I, Kirschner J, Schneider J, et al. Hepatitis C virus core antigen testing in liver and kidney transplant recipients. J Viral Hepat 2014;21:769–779.
  30. Freiman JM, Tran TM, Schumacher SG, White LF, Ongarello S, Cohn J,et al. Hepatitis C core antigen testing for diagnosis of hepatitis C virusinfection: a systematic review and meta-analysis. Ann Intern Med 2016;165:345–355.
  31. Håvard Midgard, Amanda Weir, et al. HCV epidemiology in high-risk groups and the risk of reinfection. J Hepatology 2016;65:33-45.
  32.  WHO. Global health sector strategy on viral hepatitis, 2016–2021. Available from: http://www.who.int/hepatitis/strategy2016-2021.
  33. Arase Y, Ikeda K, Chayama K, Murashima N, Tsubota A, Suzuki Y, et al. Fluctuation patterns of HCV-RNA serum level in patients with chronic hepatitis C. J Gastroenterol 2000;35:221–225.
  34. Cividini A, Cerino A, Muzzi A, Furione M, Rebucci C, Segagni L, et al. Kinetics and significance of serum hepatitis C virus core antigen in patients with acute hepatitis C. J Clin Microbiol 2003;41:2144-46
  35. Michael J. Zoratti, et al. Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: A systematic literature review and meta-analysis. E Clinical Medicine. 2020 Jan; 18: 100237.
  36. Amir A. Qamar, Norman D. Grace, et al. Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. Clinical gastroenterology and hepatology 2009;7:689-695.
  37. Sheehan, Vivien A., et al. Hepatitis C and neutropenia. Current Opinion in Hematology 2014;21:58-63.
  38. Weksler B B. Review article: the pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease. Aliment Pharmacol Ther 2007: Nov;26 (Suppl 1):13-9.
  39. Zohair Ahmed, Umair, et al. Liver function tests in identifying patients with liver disease. Clin Exp Gastroenterol. 2018;11:301-307.
  40. Saxena, V. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 2016;36:807-816.
  41. Bhamidimarri, K. R. Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of hepatitis C in patients with end stage renal disease. J. Hepatol. 2015;63: 763-765.
  42. Uroš Karić, et al. FIB-4 and APRI scores for predicting severe fibrosis in chronic hepatitis C - a developing country"s perspective in DAA era.  J Infect Dev Ctries 2018; 12(3):178-182.
  43. Michael F. Harrison. The Misunderstood Coagulopathy of Liver Disease: A Review for the Acute Setting. West J Emerg Med. 2018 Sep; 19(5): 863-871.
  44. Gupta, S. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systemic review and critical analysis. Med. 2003;139:46-50.
  45. Di Bisceglie, A. M. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J. Hepatol. 2005;43:434- 441.
  46. AASLD-IDSA Pannel on HCV Guidance. 2016. Monitoring patients who are starting hepatitis C treatment, are on treatment, or have completed therapy. Recommendations for testing, managing, and treating hepatitis C. AASLD-IDSA, Alexandria, VA. http://hcvguidelines.org/full-report/monitoring-patients-who-are-starting-hepatitis-c-treatment-are-treatment-or-have. Accessed 22 March 2016.
  47. Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysis. Wellcome Open Research 2019, 4:132 Last updated: 13 Nov 2019.
  48. Sarrazin C, Isakov V, Svarovskaia ES, Hedskog C, Martin R, Chodavarapu K, et al. Late relapse versus hepatitis C virus reinfection in patients with sustained virologic response after sofosbuvir-based therapies. Clin Infect Dis 2017;64:44-52.
  49. Chevaliez S, Pawlotsky JM. Diagnosis and management of chronic viral hepatitis: antigens, antibodies and viral genomes. Best Pract Res Clin Gastroenterol 2008;22:1031–1048.
  50. Kamili S, Drobeniuc J, Araujo AC, Hayden TM. Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis 2012;55:43-48.
  51. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000;6:578–582.
  52. Кулюшина, Е. А. Возможности ультразвукового исследования в диагностике хронических гепатитов и циррозов печени с позиций доказательной медицины. Медицинская визуализация. – 2009. – № 6. – С. 122 – 124.
  53. Singal, A. Meta-analysis: surveillance with ultrasound for early stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30:37-47.
  54. Castera, L. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J. Hepatol. 2010;52:191-198.
  55. Tsochatzis, E. A. Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C. Hepatology. 2014;60(3):832-843.
  56. Zhang, W. Liver stiffness measurement, better than APRI, Fibroindex, Fib-4, and NBI gastroscopy, predicts portal hypertension in patients with cirrhosis. Cell Biochem Biophys. 2015;71(2):865-873.
  57. Castera, L. Noninvasive evaluation of portal hypertension using transient elastography. J. Hepatol. 2012;56(3):696-703.
  58. Chen, T., et al. Occult cirrhosis diagnosed by transient elastography is a frequent and under-monitored clinical entity. Liver Int. 2015;35(10):2285-2293.
  59. Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 2017;15 2:142-56.
  60. Шерцингер, А. Г. Роль эндоскопии в выборе лечения больных портальной гипертензией. Анналы хирургической гепатологии. – 2015. – T. 20(2). – P. С. 20 – 30.
  61. Thabut D, Bureau C, Layese R, Bourcier V, Hammouche M, Cagnot C, et al. Validationof Baveno VI criteria for screening and surveillance of esophageal varices in patients with compensated cirrhosis and a sustained response to antiviral therapy. Gastroenterology 2019;156:997–1009.
  62. Кулюшина, Е. А. Синдромальный подход в лучевой диагностике цирроза печени. Клинические перспективы гастроэнтерологии, гепатологии. – 2009. – T. 6. – С.10 – 16.
  63. Трефилов, А. А. Лучевая диагностика гепатоцеллюлярного рака на фоне цирроза печени. Диагностическая и интервенционная радиология. – 2014. –T. 8(2-2). – С. 70 – 80.
  64. Teefey, S. A. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology 2003;226:533-542.
  65. Ющук, Н. Д. Протокол диагностики и лечения больных вирусными гепатитами В и С. Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2010. – T. 20(6). – С. 4 – 60.
  66. Chen, T. Occult cirrhosis diagnosed by transient elastography is a frequent and under-monitored clinical entity. Liver Int. 2015;35(10):2285-2293.
  67. Шерцингер, А. Г. Роль эндоскопии в выборе лечения больных портальной гипертензией. Анналы хирургической гепатологии. – 2015. – T. 20(2). – P. С. 20 – 30.
  68. Zehui Yan, Yuming Wang. Viral and host factors associated with outcomes of hepatitis C virus infection (review). Molecular medicine reports 2017;15(5):2909-2924.
  69. Jakobsen JC, Nielsen EE, Feinberg J, et al. Direct-acting antivirals for chronic hepatitis C (Review). Cochrane Database of Systematic Reviews 2017, Issue 6. Art. No.: CD012143.
  70. Benjamin Schulte, Maximilian Wübbolding, Fiona Marra, et al. Frequency of Potential Drug–Drug Interactions in the Changing Field of HCV Therapy. Open Forum Infectious Diseases 2020;7(2), https://doi.org/10.1093/ofid/ofaa040.
  71. Pawlotsky JM. Retreatment of hepatitis C virus-infected patients with direct-acting antiviral failures. Semin Liver Dis 2019;39:354-368.
  72. Vermehren J, Susser S, Dietz J, von Hahn T, Petersen J, Hinrichsen H, et al. Retreatment of patients who failed DAA-combination therapies: realworld experience from a large hepatitis C resistance database. J Hepatol 2016;64(2):188.
  73. Sorbo MC, Cento V, Di Maio VC, Howe AYM, Garcia F, Perno CF, et al. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: update 2018. Drug Resist Updat 2018;37:17-39.
  74. Poordad F, Pol S, Asatryan A, Buti M, Shaw D, Hezode C, et al. Glecaprevir/ pibrentasvir in patients with HCV genotype 1 or 4 and prior directacting antiviral treatment failure. Hepatology 2018;67:1253-1260.
  75. Wyles D, Weiland O, Yao B, Weilert F, Dufour JF, Gordon SC, et al. Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. J Hepatol 2019;70:1019-1023.
  76. Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015;373:2599-2607.
  77. Foster GR, Afdhal N, Roberts SK, Brau N, Gane EJ, Pianko S, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015;373:2608-2617.
  78. Esteban R, Pineda JA, Calleja JL, Casado M, Rodriguez M, Turnes J, et al. Efficacy of sofosbuvir and velpatasvir, with and without ribavirin, in patients with hepatitis C virus genotype 3 infection and cirrhosis. Gastroenterology 2018;155:1120-1127.
  79. Mangia A, Milligan S, Khalili M, Fagiuoli S, Shafran S, Carrat F, et al. Global real-world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: integrated analysis of 12 clinical practice cohorts. J Hepatol 2019;70(Suppl.).
  80. Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, et al. Glecaprevir- pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med 2018;378:354–369.
  81. Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol 2017;67:263-271.
  82. Toyoda H, Chayama K, Suzuki F, Sato K, Atarashi T, Watanabe T, et al. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. Hepatology 2018;67:505-513.
  83. Flamm SL, Wyles DL, Wang S, Mutimer DJ, Rockstroh JK, Horsmans YJ, et al. Efficacy and safety of glecaprevir/pibrentasvir for 8 or 12 weeks in treatment-naïve patients with chronic HCV genotype 3: an integrated Phase 2/3 analysis. Hepatology 2017;66(Suppl.):35A.
  84. Krishnan P, Schnell G, Tripathi R, Ng T, Reisch T, Beyer J, et al. Pooled resistance analysis in HCV genotype 1-6-infected patients treated with glecaprevir/pibrentasvir in phase 2 and 3 clinical trials. J Hepatol 2017;66(Suppl. 1):500.
  85. Wei L, Wang G, Alami NN, Xie W, Heo J, Xie Q, et al. Glecaprevirpibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies - a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2). Lancet Gastroenterol Hepatol 2020;5:839-849.
  86. Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 2017;17:1062-1068.
  87. Wyles D, Poordad F, Wang S, Alric L, Felizarta F, Kwo PY, et al. Glecaprevir/ pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: a partially randomized phase 3 clinical trial. Hepatology 2018;67:514-523.
  88. Brown Jr RS, Buti M, Rodrigues L, Chulanov V, Chuang WL, Aguilar H, et al. Glecaprevir/pibrentasvir for 8 weeks in treatment-naive patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial. J Hepatol 2020;72:441-449.
  89. Gupta N, Mbituyumuremyi A, Kabahizi J, Ntaganda F, Muvunyi CM, Shumbusho F, et al. Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial. Lancet Gastroenterol Hepatol 2019;4:119-126.
  90. Zeng QL, Xu GH, Zhang JY, Li W, Zhang DW, Li ZQ, et al. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: a real-life observational study. J Hepatol 2017;66:1123-1129.
  91. Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 2016;16:685-697.
  92. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown Jr RS, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015;149:649-659.
  93. Jacobson IM, Lawitz E, Kwo PY, Hezode C, Peng CY, Howe AYM, et al. Safety and efficacy of elbasvir/grazoprevir in patients with hepatitis C virus infection and compensated cirrhosis: an integrated analysis. Gastroenterology 2017;152:1372-1382.
  94. Zeuzem S, Serfaty L, Vierling J, ChengW, George J, Sperl J, et al. The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. J Gastroenterol 2018;53:679-688.
  95. Kramer JR, Puenpatom A, Erickson KF, Cao Y, Smith D, El-Serag HB, et al. Real-world effectiveness of elbasvir/grazoprevir in HCV-infected patients in the US Veterans Affairs Healthcare System. J Viral Hepat 2018;25:1270-1279.
  96. Flamm SL, Bacon B, Curry MP, Milligan S, Nwankwo CU, Tsai N, et al. Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network. Aliment Pharmacol Ther 2018;47:1511-1522.
  97. Hernandez-Conde M, Fernandez I, Perello C, Gallego A, Bonacci M, Pascasio JM, et al. Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: results from the Spanish HEPA-C real-world cohort. J Viral Hepat 2019;26:55-64.
  98. Wedemeyer H, Craxi A, Zuckerman E, Dieterich D, Flisiak R, Roberts SK, et al. Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: a meta-analysis. J Viral Hepat 2017;24:936–943.
  99. Welzel TM, Asselah T, Dumas EO, Zeuzem S, Shaw D, Hazzan R, et al. Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, Phase 3b trial. Lancet Gastroenterol Hepatol 2017;2:494–500.
  100. Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment- experienced patients with HCV genotype 1b infection. Gastroenterology 2014;147:359–365.
  101. Agarwal K, Dumas EO, Gaeta GB, Lee S, Streinu-Cercel A, Schott E, et al. Long-term clinical outcomes in HCV genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin: first interim safety and efficacy results from TOPAZ-I. Hepatology 2016;64:427.
  102. Welzel TM, Isakov V, Trinh R, Streinu-Cercel A, Dufour JF, Marinho RT, et al. Efficacy and safety of ombitasvir, paritaprevir/ritonavir and dasabuvir without ribavirin in patients with HCV genotype 1b with or without compensated cirrhosis: pooled analysis across 5 clinical trials. J Hepatol 2016;64:824.
  103. Wei L, Hou J, Luo Y, Heo J, Chu CJ, Duan ZP, et al. ONYX-I: safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir in Asian adults with genotype 1b chronic hepatitis C virus (HCV) infection. A randomized, double-blind, placebo-controlled study. Hepatology 2016;64:432A.
  104. Feld JJ, Moreno C, Trinh R, Tam E, Bourgeois S, Horsmans Y, et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks. J Hepatol 2016;64:301–307.
  105. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T,Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211–221.
  106. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 2016;63:1493–1505.
  107. Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All- Oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 Phase 3 Study. Hepatology 2015;61:1127–1135.
  108. Leroy V, Angus P, Bronowicki JP, Dore GJ, Hezode C, Pianko S, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). Hepatology 2016;63:1430–1441.
  109.  Климова Е.А., Бурневич Э.З., Чуланов В.П. и соавт. Эффективность и безопасность безинтерфероновой комбинации нарлапревир/ритонавир и даклатасвир в популяции российских пациентов с хроническим гепатитом С. Tер. архив. – 2019. –  № 91(8). – С. 67 – 73.
  110. Климова Е.А., Бурневич Э.З., Чуланов В.П. и соавт. Нарлапревир, ритонавир и софосбувир у пациентов с хроническим гепатитом С, инфицированных генотипом 1 вируса, без цирроза печени. Инф. болезни: новости, мнения, обучение. – 2020. Том 9, № 1 (9). – С. 50 – 56.
  111. Terrault NA, Pawlotsky JM, McHutchison J, Anderson F, Krajden M, Gordon S, et al. Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy. J Viral Hepat 2005;12:465-472.
  112. Pierre Pradat, et al. Ribavirin at the era of novel direct antiviral agents for the treatment of hepatitis c virus infection: relevance of pharmacological monitoring. Advances in Hepatology Volume 2014, Article ID 493087, 13 pages.
  113. Ludovico Abenavoli, Marta Mazza, Piero L. Almasio. The optimal dose of ribavirin for chronic hepatitis C: From literature evidence to clinical practice. Hepat Mon. 2011;11(4):240-246.
  114. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales Jr FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
  115. Hadziyannis SJ, Sette Jr H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355.
  116. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
  117. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36(Suppl. 1):S237-S244.
  118. Kalyan RB, Sanjaya KS, Paul M. Hepatitis C Virus and Liver Transplantation. Gastroenterology & Hepatology 2017;13(4):214-220.
  119. Gee I, Alexander G. Liver transplantation for hepatitis C virus related liver disease. Postgrad Med J 2005;81:765-771.
  120. Elizabeth C Verna, Robert S Brown, Jr. Hepatitis C virus infection in liver transplant candidates and recipients. Last updated: Apr 12, 2021 on https://www.uptodate.com/.
  121. Ríos Castellanos, E. Endoscopic injection of cyanoacrylate glue versus other endoscopic procedures for acute bleeding gastric varices in people with portal hypertension. Cosp. Cochrane Database Syst Rev. 2015;5:1018.
  122. Хубутия, М. Ш. Эндоскопическое лигирование в остановке и профилактике кровотечения из варикозно расширенных вен пищевода и желудка/ М. Ш. Хубутия, Т. П. Пинчук, С. С. Согрешилин// Клинические перспективы гастроэнтерологии, гепатологии. – 2012. – V. 1. – P. 10 – 15.
  123. Шишин, К. В. Лигирование варикозно расширенных вен пищевода как метод профилактики кровотечений портального генеза/ К. В. Шишин, И. Г. Бакулин, И. Ю. Недолужко// Фарматека. – 2016. – V. 2. – P. 31 – 35.
  124. Fagiuoli, S. Consensus conference on TIPS management: Techniques, indications, contraindications/ S. Fagiuoli, R. Bruno, W. Debernardi Venon et al.// AISF TIPS Special Conference. Dig Liver Dis. 2017;49(2):121-137.
  125. Khan, S. Portosystemic shunts versus endoscopic therapy for variceal rebleeding in patients with cirrhosis/ S. Khan, S. C. Tudur, P. Williamson, R. Sutton// Cochrane Database Syst Rev. 2006;4:553.
  126. Aithal GP, Palaniyappan N, China L, et al. Guidelines on the management of ascites in cirrhosis. Gut. 2021;70(1):9-29.
  127. Negro F, Forton D, Craxi A, Sulkowski MS, Feld JJ, Manns MP. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology 2015;149:1345-1360.
  128. Mahale P, Engels EA, Li R, Torres HA, Hwang LY, Brown EL, et al. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection. Gut 2018;67:553-561.
  129. Negro F. Expanded benefits of curing the extrahepatic manifestations of HCV infection. Gut 2018;67:1917-1919.
  130. Lacombe, K. HIV and viral hepatitis coinfections: advances and challenges. Gut 2012;61(Suppl 1):47-58.
  131. Qurishi, N. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003;22, 362 (9397):1708-1713.
  132. Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015;373:705-713.
  133. Townsend KS, Osinusi A, Nelson AK, Kohli A, Gross C, Polis MA, et al. High efficacy of sofosbuvir/ledipasvir for the treatment of HCV genotype 1 in patients coinfected with HIV on and off antiretroviral therapy: results from the NIAID ERADICATE trial. Hepatology 2014;60:240A-241A.
  134. Wyles D, Brau N, Kottilil S, Daar E, Workowski K, Luetkemeyer A, et al. Sofosbuvir/velpatasvir fixed dose combination for 12 weeks in patients coinfected with HCV and HIV-1: the Phase 3 ASTRAL-5 study. J Hepatol 2016;64:S188-S189.
  135. Wyles DL, Sulkowski MS, Eron JJ, Trinh R, Lalezari J, Slim J, et al. TURQUOISE-I: 94% SVR12 in HCV/HIV-1 coinfected patients treated with ABT-450/r/ombitasvir, dasabuvir and ribavirin. Hepatology 2014;60:1136A-1137A.
  136. Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE COINFECTION): a non-randomised, open-label trial. Lancet HIV 2015;2:e319-e327.
  137. Luetkemeyer AF, McDonald C, Ramgopal M, Noviello S, Bhore R, Ackerman P. 12 weeks of daclatasvir in combination with sofosbuvir for HIV-HCV coinfection (ALLY-2 study): efficacy and safety by HIV combination antiretroviral regimens. Clin Infect Dis 2016;62:1489-1496.
  138. Konstantinou D, Deutsch M. The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viral interactions and management.  Ann Gastroenterol 2015;28:221-8.
  139. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998;75(3):347-54.
  140. De Monte A, Courjon J, Anty R, Cua E, Naqvi A, Mondain V, et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge. J Clin Virol 2016;78:27-30.
  141. Wang C, Ji D, Chen J, Shao Q, Li B, Liu J, et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol 2017;15:132-136.
  142. Marcus M Mücke,et al. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2018 Mar;3(3):172-180.
  143. Yi-Fen Shih, Chun-Jen Liu. Hepatitis c virus and hepatitis B virus co-infection. Viruses. 2020;12(7):741.
  144. Calvaruso V, Ferraro D, Licata A, Bavetta MG, Petta S, Bronte F, et al. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals. J Viral Hepat. 2018;25:72-79.
  145.  Belperio PS, Shahoumian TA, Mole LA, Backus LI. Evaluation of hepatitis B reactivation among 62920 veterans treated with oral hepatitis C antivirals. Hepatology 2017;66:27-36.
  146. Pockros PJ, Reddy KR, Mantry PS, Cohen E, Bennett M, Sulkowski MS, et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology 2016;150:1590-1598.
  147. Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour Jr H, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4– 5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 2015;386:1537-1545.
  148. Bruchfeld A, Roth D, Martin P, Nelson DR, Pol S, Londono MC, et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4–5 chronic kidney disease: clinical, virological, and healthrelated quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol 2017;2:585-594.
  149. Kramer JR, Puenpatom A, Erickson K, Cao Y, Smith DL, El-Serag HB, et al. Effectiveness of elbasvir/grazoprevir in patients with chronic hepatitis C and chronic kidney disease: results from the Veterans Affairs system.Hepatology 2017;66:597A.
  150. Cornberg M, Negro F, Lampertico P, Turne s J, Curry M, Brown A, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection: a meta-analysis. J Hepatol 2019;70:e113 e114.
  151. Gane E, Lawitz E, Pugatch D, Papatheodoridis G, Brau N, Brown A, et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med 2017;377:1448-1455.
  152. Pol S, Pockros P, Pugatch D, Brau N, Landis C, Elkhashab M, et al. Safety and efficacy of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection genotype 1-6 and chronic kidney disease: an integrated analysis. J Hepatol 2017;66(Suppl. 1):S738.
  153. Lawitz E, Landis CS, Flamm SL, Bonacini M, Ortiz-Lasanta G, Huang J, et al. Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study. Lancet Gastroenterol Hepatol 2020. Epub ahead of print.
  154. Borgia SM, Dearden J, Yoshida EM, Shafran SD, Brown A, Ben-Ari Z, et al. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. J Hepatol 2019;71:660-665.
  155. Cox-North P, Hawkins KL, Rossiter ST, Hawley MN, Bhattacharya R, Landis CS. Sofosbuvir-based regimens for the treatment of chronic hepatitis C in severe renal dysfunction. Hepatol Commun 2017;1:248-255.
  156. Poustchi H, et al. The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment. J Gastroenterol Hepatol. 2020 Sep;35(9):1590-1594.
  157. Mingshu Li, Jun Chen, Zhixiong Fang, et al. Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4-5 chronic kidney disease: a systematic review and meta-analysis. Virology Journal 2019;16:34.
  158. Gane E, Pilmore H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation 2002;74:427-437.
  159.  Perricone G, Duvoux C, Berenguer M, Cortesi PA, Vinaixa C, Facchetti R, et al. Delisting HCV-infected liver transplant candidates who improved after viral eradication: outcome 2 years after delisting. Liver Int 2018;38:2170-2177.
  160. Pascasio JM, Vinaixa C, Ferrer MT, Colmenero J, Rubin A, Castells L, et al. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. J Hepatol 2017;67:1168-1176.
  161. El-Sherif O, Jiang ZG, Tapper EB, Huang KC, Zhong A, Osinusi A, et al. Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection. Gastroenterology 2018;154:2111-2121.
  162. Коробка В.Л., и соавт. Развитие рекомпенсации у больных  HCV-ассоциированным декомпенсированны циррозом печени после терапии современными препаратами прямого противовирусного действия. Доказательная гастроэнтерология  2019;8(4-5):11-21.
  163. Сюткин В.Е., и соавт. Современные тенденции в лечении гепатита С до и после трансплантации печени. Инфекционные болезни 2020;18(2):5-13.
  164. Хубутия М.Ш., и соавт. Рекомендации по профилактике и лечению инфекций вирусами гепатита В и С у больных, находящихся в Листе ожидания трансплантации печени, и реципиентов печени. Трансплантология 2020;12(3):231-244.
  165. Cortesi PA, et al. The optimal timing of hepatitis C therapy in liver transplant-eligible patients: Cost-effectiveness analysis of new opportunities. J Viral Hepat 2018 Jul;25(7):791-801.
  166. Jagpreet Chhatwal, et al. Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. Hepatology 2017 Mar;65(3):777-788.
  167. Curry MP, O’Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015;373:2618-2628.
  168.  Lu M,Wu KH, Li J, Moorman AC, Spradling PR, Teshale EH, et al. Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure. J Viral Hepat 2019;26:1210-1217.
  169. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 2016;63:1493–1505.
  170. Michael Charlton, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of hcv infection in patients with advanced liver disease. Gastroenterology 2015;149(3):649-659.
  171. Chen-Hua Liu, et al. Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan. PLoS One, published on December 21, 2018:  https://doi.org/10.1371/journal.pone.0209299.
  172. Charlton MR, Cheung MC, Manns MP, Sajed N, Troke P, Spellman JG, et al. Ledipasvir/sofosbuvir + ribavirin (LDV/SOF + RBV) for 12 weeks in decompensated HCV genotype 1 patients: SOLAR-1 and -2 studies compared to a real-world dataset. Hepatology 2016;64:489A-490A.
  173. Flamm SL, Everson GT, Charlton M, Denning JM, Arterburn S, Brandt- Sarif T, et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study. Hepatology 2014;60:320A.
  174. Хубутия М.Ш., и соавт. Лечение гепатита C у реципиентов печени в Московском центре трансплантации печенив течение 10 лет. Трансплантология 2013;2:5-12.
  175. Сюткин В.Е., Е.Н. Бессонова  М.Н. Терапия возвратного гепатита C после трансплантации печени препаратами прямого противовирусного действия: опыт трёх российских центров. Эпидемиология и инфекционные болезни, 2018;23(1):4-14.
  176. Berenguer M, et al. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008 Mar;8(3):679-87.
  177. Picciotto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo GG, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007;46:459-465.
  178. Хубутия М.Ш., et al., Применение софосбувира для лечения возвратного гепатита С после трансплантации печени. Трансплантология, 2017;9(1):13-22.
  179. Brown R. S. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. Liver Transpl. 2016;22(1):24-33.
  180. Agarwal K, Castells L, Mullhaupt B, Rosenberg WMC, McNabb B, Arterburn S, et al. Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients. J Hepatol 2018;69:603-607.
  181. Eisenberger U, Guberina H, Willuweit K, Bienholz A, Kribben A, Gerken G, et al. Successful treatment of chronic hepatitis C virus infection with sofosbuvir and ledipasvir in renal transplant recipients. Transplantation 2017;101:980-986.
  182. Reau N, Kwo PY, Rhee S, Brown RS, Agarwal K, Angus P, et al. MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1–6 infection. J Hepatol 2017;66:90.
  183. Ian A. Rowe, et al. Hepatitis A virus vaccination in persons with hepatitis C virus infection: Consequences of Quality Measure Implementation. Hepatology 2012; 56(2):501-6.
  184. Jiaye Liu, Hui Wu, Hui Chen. Immune response to hepatitis B vaccine in patients with chronic hepatitis C infection: A systematic review and meta-analysis. Hepatol Res 2018 Feb;48(2):119-126.
  185. Jennifer R. Kramer, et al. Meeting vaccination quality measures for hepatitis A and B virus in patients with chronic hepatitis C infection. Hepatology 2011; 53(1):42-52.
  186. Emily Henkle, et al. Hepatitis A and B Immunity and Vaccination in Chronic Hepatitis B and C Patients in a Large United States Cohort. Clinical Infectious Diseases 2015;60(4):514-522.
  187. Xiaofei Gao, et al. Prevalence and trend of hepatitis C virus infection among blood donors in Chinese mainland: a systematic review and meta-analysis. BMC Infectious Diseases 2011;11:88.
  188. Pozzetto B, Memmi M, Garraud O, et al.  Health care-associated hepatitis C virus infection. World J Gastroenterol. 2014; 20(46):17265-17278.
  189. Thursz M, Fontanet A. HCV transmission in industrialized countries and resource-constrained areas. Gastroenterol. Hepatol.2014;11:28–35.
  190. Alastair Heffernan, et al. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Lancet. 2019 Mar 30;393(10178):1319-1329.
  191. Conte D, Fraquelli M, Prati D, Colucci A, Minola E. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology. 2000;31(3):751-755.
  192. Gervais A, Bacq Y, Bernuau J, Martinot M, Auperin A, Boyer N, et al. Decrease in serum ALT and increase in serum HCV RNA during pregnancy in women with chronic hepatitis C. J Hepatol. 2000;32(2):293-299.
  193. Jhaveri R, Hashem M, El-Kamary SS, Saleh D"aA, Sharaf SA, El-Mougy F, et al. Hepatitis C virus (HCV) vertical transmission in 12-month-old infants born to HCV-infected women and assessment of maternal risk factors. Open Forum Infect Dis. 2015;2(2):89.
  194. Shebl FM, El-Kamary SS, Saleh D"aA, et al. Prospective cohort study of mother-to-infant infection and clearance of hepatitis C in rural Egyptian villages. J Med Virol. 2009;81(6):1024-1031.
  195. Puljic A, Salati J, Doss A, Caughey AB. Outcomes of pregnancies complicated by liver cirrhosis, portal hypertension, or esophageal varices. J Matern Fetal Neonatal Med. 2016;29(3):506-509.
  196. Tan J, Surti B, Saab S. Pregnancy and cirrhosis. Liver Transpl. 2008;14(8):1081-1091.
  197. Rosalia Ragusa, et al. Hepatitis C Virus Infection in Children and Pregnant Women: An Updated Review of the Literature on Screening and Treatments. AJP Rep. 2020 Jan; 10(1): 121-127.
  198. Санитарно-эпидемиологические правила СП 3.1.3112-13 "Профилактика вирусного гепатита С" (утв. постановлением Главного государственного санитарного врача РФ от 22 октября 2013 г. N 58).
  199. Chappell CA, Krans EE, Bunge K, et al. A phase 1 study of ledipasvir/sofosbuvir in pregnant women with hepatitis C virus [abstract 87]. Conference on Retroviruses and Opportunistic Infections. Seattle, WA; 2019.
  200. Yattoo GN. Treatment of chronic hepatitis C with ledipasvir/sofosbuvir combination during pregnancy [Abstract]. Hepatol Int. 2018;12(2):292-293.
  201. Susan M. Sinclair, et al. The Ribavirin Pregnancy Registry: An Interim Analysis of Potential Teratogenicity at the Mid-Point of Enrollment. Drug Saf 2017;40:1205–1218.
  202. Anna Maria Spera, Tarek Kamal Eldin, Grazia Tosone, Raffaele Orlando. Antiviral therapy for hepatitis C: has anything changed for pregnant/lactating women? World J Hepatol. 2016;8(12): 557–565.
  203. Centers for Disease Control and Prevention (CDC). Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47(RR-19):1-39.
  204. Resti M, Azzari C, Mannelli F, Moriondo M, Novembre E, de Martino M, et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany study group on hepatitis C virus infection. BMJ. 1998;317(7156):437-441.
  205. Gregory J Dore, et al. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. J Hepatol 2020 Mar;72(3):431-440.
  206. JS Davis, et al. Minimal Compared With Standard Monitoring During Sofosbuvir-Based Hepatitis C Treatment: A Randomized Controlled Trial. Open Forum Infect Dis. 2020 Feb; 7(2): ofaa022.
  207. Chandana Papudesu, et al. Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection. Hepatol Int DOI 10.1007/s12072-016-9761-2.
  208. Ossama Ashraf Ahmed, et al. Sofosbuvir Plus Daclatasvir in Treatment of Chronic Hepatitis C Genotype 4 Infection in a Cohort of Egyptian Patients: An Experiment the Size of Egyptian Village. Hindawi International Journal of Hepatology Volume 2018, Article ID 9616234, 5 pages https://doi.org/10.1155/2018/9616234.
  209. Гусев Д.А., Климова Е.А., Знойко О.О. и соавт. Эффективность и безопасность 8-недельной терапии хронического гепатита С комбинацией препаратов, включающей ингибитор протеазы нарлапревир. Инфекционные болезни: новости, мнения, обучение 2020;9(3):41-48.
  210. Raffaella Lionetti, et al. Daclatasvir, sofosbuvir with or without ribavirin for 24 weeks in hepatitis C genotype 3 cirrhosis: A real-life study. Annals of Hepatology 18 (2019) 434-438.
  211. H. Omar, et al. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. Aliment Pharmacol Ther. 2017;1-11.
  212. Gane EJ, et al. Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen. Hepatology. 2017 Oct;66(4):1083-1089.
  213. Afdhal N, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.N Engl J Med 2014 May 15;370(20):1889-98.
  214. Gane E, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. Gastroenterology 2015;149:1454-64.
  215. Buggisch P, et al. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany. PLoS One 2019;14:e0214795.
  216. Shiha G, et al. Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt. Gut 2019;68:721-8.
  217. Abergel A, et al. Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Hepatology 2016;64:1049-56.
  218. Bourgeois S, et al. Prescription and efficacy of daclatasvir and sofosbuvir ± ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries: The CMPASS-EU cohort study. COGENT MEDICINE 2020;7(1).
  219. Sulkowski MS, et al. Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection. N Engl J Med 2014 Jan 16;370(3):211-21.
  220. Pol S, et al. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. J Hepatol 2017 Jan;66(1):39-47.
  221. Chung-Feng Huang, et al. An open-label, randomized, active control trial of 8 versus 12 weeks of elbasvir/grazoprevir for treatment-naïve chronic hepatitis C genotype 1b patients with mild fibrosis (EGALITE): Impact of baseline viral loads and NS5A resistance-associated substitution. J Infect Dis 2019 Jul 19;220(4):557-566.
  222. Tarik Asselah, et al. Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: a randomized study. Liver Int 2020 May;40(5):1042-1051.
  223. Tarik Asselah, et al. Efficacy of Elbasvir and Grazoprevir in Participants with Hepatitis C Virus Genotype 4 Infection: A Pooled Analysis. Liver Int 2018 Sep;38(9):1583-1591.
  224. Eric Lawitz, et al. Short-duration Treatment With Elbasvir/Grazoprevir and Sofosbuvir for Hepatitis C: A Randomized Trial. Hepatology 2017 Feb;65(2):439-450.
  225. Armand Abergel, et al. Ledipasvir Plus Sofosbuvir for 12 Weeks in Patients With Hepatitis C Genotype 4 Infection. Hepatology 2016 Oct;64(4):1049-56.
  226. Allison M. Bell, et al. Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C Int J Hepatol. 2016;2016:3852126.
  227. Tania M Welzel, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut. 2016 Nov;65(11):1861-1870.
  228. Gregory J Dore, et al. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. J Hepatol. 2020 Mar;72(3):431-440.
  229. Pietro Lampertico, et al. Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naı¨ve Patients with Compensated Cirrhosis. Adv Ther. 2020 Sep;37(9):4033-4042.
  230. Saifu H. N., et al. Evaluation of human immunodeficiency virus and hepatitis C telemedicine clinics Am J Manag Care. 2012 Apr;18(4):207-12.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*